ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 128 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,748 | -92.0% | 10,967 | -88.7% | 0.00% | – |
| Q2 2023 | $134,405 | -86.6% | 96,694 | -38.5% | 0.00% | -100.0% |
| Q2 2022 | $1,000,000 | +209.6% | 157,300 | +144.0% | 0.00% | – |
| Q4 2021 | $323,000 | -89.1% | 64,478 | +11.6% | 0.00% | -100.0% |
| Q2 2020 | $2,965,000 | +193.0% | 57,800 | +165.6% | 0.00% | +200.0% |
| Q2 2019 | $1,012,000 | -21.0% | 21,763 | -21.9% | 0.00% | -50.0% |
| Q4 2018 | $1,281,000 | -85.1% | 27,853 | -85.6% | 0.00% | -81.8% |
| Q3 2018 | $8,590,000 | +1955.0% | 193,600 | +1717.0% | 0.01% | +1000.0% |
| Q2 2018 | $418,000 | +147.3% | 10,655 | +315.9% | 0.00% | – |
| Q4 2017 | $169,000 | -99.3% | 2,562 | -99.4% | 0.00% | -100.0% |
| Q3 2017 | $23,259,000 | -65.8% | 464,069 | -68.5% | 0.04% | -71.2% |
| Q2 2017 | $68,088,000 | +278.1% | 1,471,238 | +188.5% | 0.13% | +256.8% |
| Q1 2017 | $18,008,000 | – | 509,976 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |